Answer
Yes, Kadcyla (trastuzumab emtansine) is contraindicated in people with hypersensitivity to its active substance or any of the excipients listed in section 6.1 of its product information.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.3 Contraindications · Version 18Document updated
Sources checked